Industry / Argentina
ANMAT Follows US FDA's Lead
November 2007 | Industry NewsTwo recent decisions by Argentina's medicines regulator ANMAT that mirror directives issued by the US FDA have served to demonstrate that it is watching the US regulator closely when making decisions on patient safety. The implication being that ANMAT, like many national regulatory agencies, is increasingly relying on the US FDA's judgement rather than independently considering scientific
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
